I find this incredibly encouraging SAPHYR subanalysis: refractory PMR sarilumab (w 14w PNL taper) vs placebo (w 52w taper) ?no Sx Benefit kicks on after PNL taper stops, out to 52w Reality in practice: bit more PNL prob gives excellent Sx outcomes ABST1543 #ACR22 @RheumNow https://t.co/kGBZyULZeU